-Nikkei
Jaguar Health Receives ‘Complete’ Letter From FDA For Last Of Four Major Technical Sections For Company’s Application For Conditional Approval Of Canalevia For Chemotherapy-Induced Diarrhea In Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it was informed on September 21, 2021 by the FDA's Center for Veterinary Medicine (CVM) that the Target Animal Safety (TAS) technical section of the